Pacira BioSciences, Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Large accelerated filer
State of Incorporation
DE
Business Address
2000 SIERRA POINT PARKWAY, BRISBANE, CA, 94005
Mailing Address
2000 SIERRA POINT PARKWAY, BRISBANE, CA, 94005
Phone
650-242-8052
Fiscal Year End
1231
EIN
510619477
Financial Overview
FY2025
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| SCHEDULE 13G/A Passive ownership amendment | March 27, 2026 | View on SEC |
| 4 Insider stock transaction report | March 19, 2026 | View on SEC |
| 4/A Insider transaction amendment | March 19, 2026 | View on SEC |
| 4 Insider stock transaction report | March 19, 2026 | View on SEC |
| SCHEDULE 13D/A Beneficial ownership amendment | March 12, 2026 | View on SEC |
| 8-K Current report of material events | February 26, 2026 | View on SEC |
| 10-K Annual financial report | February 26, 2026 | View on SEC |
| 4 Insider stock transaction report | February 13, 2026 | View on SEC |
| 4 Insider stock transaction report | February 13, 2026 | View on SEC |
| 4 Insider stock transaction report | February 13, 2026 | View on SEC |
Annual Reports
10-K
February 26, 2026
- Pacira reported $685 million in total revenue for 2025, a 7% increase driven by strong EXPAREL sales.
- The company achieved $92 million in net income and maintained a strong 78% gross margin.
Insider Trading
STRONG SELL
5 insiders
7 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.